Aquestive Therapeutics Inc (NASDAQ: AQST) On Monday, started off the session at the price of On Monday, remained unchanged from the previous trading day, before settling in for the closing price of $5.49. Within the past 52 weeks, AQST’s price has moved between $1.37 and $6.23.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -4.81% annually for the last half of the decade. The company achieved an average annual earnings per share of -225.00%. With a float of $79.37 million, this company’s outstanding shares have now reached $91.06 million.
In an organization with 135 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 68.49%, operating margin of -26.03%, and the pretax margin is -44.14%.
Aquestive Therapeutics Inc (AQST) Insider Updates
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Aquestive Therapeutics Inc is 12.84%, while institutional ownership is 39.59%. The most recent insider transaction that took place on Mar 15 ’24, was worth 300,000. In this transaction Chief Innovation/Tech Officer of this company sold 50,000 shares at a rate of $6.00, taking the stock ownership to the 984,476 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Chief Innovation/Tech Officer sold 25,000 for $5.19, making the entire transaction worth $129,685. This insider now owns 1,040,371 shares in total.
Aquestive Therapeutics Inc (AQST) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.03 earnings per share (EPS) for the period topping the consensus outlook (set at -0.11) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -225.00% per share during the next fiscal year.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Aquestive Therapeutics Inc (AQST) is currently performing well based on its current performance indicators. A quick ratio of 6.98 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Let’s dig in a bit further. During the last 5-days, its volume was 1.59 million. That was inferior than the volume of 1.75 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 76.60%. Additionally, its Average True Range was 0.29.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 93.12%, which indicates a significant increase from 79.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.83% in the past 14 days, which was lower than the 70.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.79, while its 200-day Moving Average is $3.72. However, in the short run, Aquestive Therapeutics Inc’s stock first resistance to watch stands at $5.67. Second resistance stands at $5.84. The third major resistance level sits at $5.99. If the price goes on to break the first support level at $5.35, it is likely to go to the next support level at $5.20. Assuming the price breaks the second support level, the third support level stands at $5.03.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
Market capitalization of the company is 499.92 million based on 91,039K outstanding shares. Right now, sales total 50,580 K and income totals -7,870 K. The company made 20,100 K in profit during its latest quarter, and -2,750 K in sales during its previous quarter.
